Literature DB >> 25448508

Expectant management of mild preeclampsia versus superimposed preeclampsia up to 37 weeks.

Amy M Valent1, Emily A DeFranco2, Allessa Allison3, Ahmed Salem4, Lori Klarquist4, Kyle Gonzales5, Mounira Habli6, C David Adair5, Casey Armistead3, Yuping Wang7, David Lewis3, Baha Sibai8.   

Abstract

OBJECTIVE: We sought to compare maternal and neonatal outcomes of expectantly managed pregnancies complicated by chronic hypertension with superimposed preeclampsia vs mild preeclampsia up to 37 weeks of gestation. STUDY
DESIGN: This was a multicenter retrospective cohort study of all pregnancies complicated by chronic hypertension with superimposed preeclampsia or mild preeclampsia expectantly managed in the hospital from January 2008 through December 2011. The primary outcomes, adverse maternal and neonatal composite morbidities, were compared between these 2 groups. Frequency differences of maternal adverse outcomes were stratified by gestational age at delivery of <34 and 34-36(6/7) weeks of gestation.
RESULTS: We found no significant differences in rates of neonatal composite morbidity or latency periods between women with superimposed preeclampsia and mild preeclampsia. Adverse neonatal outcomes were significantly higher at <34 compared to 34-36(6/7) weeks of gestation (97-98% vs 48-50%) in both cohorts. Maternal adverse composite outcome occurred more frequently in women with superimposed preeclampsia compared to mild preeclampsia (15% vs 5%; P = .003; relative risk, 3.0; 95% confidence interval, 1.45-6.29).
CONCLUSION: Women with superimposed preeclampsia have similar neonatal outcomes but more maternal complications than women with preeclampsia without severe features who are expectantly managed <37 weeks.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  expectant management; hypertension; preeclampsia

Mesh:

Year:  2014        PMID: 25448508     DOI: 10.1016/j.ajog.2014.10.1090

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Identification of Patients with Preeclampsia by Measuring Fluorescence of an Amyloid-Binding Aryl Cyano Amide in Human Urine Samples.

Authors:  Jamie P Do; Kevin J Cao; Sylvia Wei; Louise C Laurent; Mana M Parast; Jerry Yang
Journal:  Anal Chem       Date:  2018-12-03       Impact factor: 6.986

2.  A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone.

Authors:  Kaoru Yamashita; Satoshi Morimoto; Yuko Inoue; Kiyotaka Hirata; Shihori Kimura; Yasufumi Seki; Kanako Bokuda; Daisuke Watanabe; Atsuhiro Ichihara
Journal:  J Endocr Soc       Date:  2022-05-29

3.  Expectant Management of Hypertensive Disorders of Pregnancy and Future Cardiovascular Morbidity.

Authors:  Joshua I Rosenbloom; Adam K Lewkowitz; Kathryn J Lindley; D Michael Nelson; George A Macones; Alison G Cahill; Margaret A Olsen; Molly J Stout
Journal:  Obstet Gynecol       Date:  2020-01       Impact factor: 7.623

4.  Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.

Authors:  Tu'uhevaha J Kaitu'u-Lino; Fiona C Brownfoot; Sally Beard; Ping Cannon; Roxanne Hastie; Tuong V Nguyen; Natalie K Binder; Stephen Tong; Natalie J Hannan
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

5.  Clinical Utility of Weekly Laboratory Testing in the Outpatient Management of Preeclampsia and Gestational Hypertension.

Authors:  John A Morgan; Lauren E McCalmont; Craig V Towers; Melissa Davis; Miriam Hankins; Niyati Rangnekar; Mary Ellen McNeal; David F Lewis
Journal:  AJP Rep       Date:  2020-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.